New Study: Stem Cell Field is Infected with Hype
By Michael Hiltzik,
Los Angeles Times
| 03. 31. 2015
Untitled Document
When billions of dollars are at stake in scientific research, researchers quickly learn that optimism sells.
A new study published in Science Translational Medicine offers a window into how hype arises in the interaction between the media and scientific researchers, and how resistant the hype machine is to hard, cold reality. The report's focus is on overly optimistic reporting on potential stem cell therapies. Its findings are discouraging.
The study by Timothy Caulfield and Kalina Kamenova of the University of Alberta law school (Caulfield is also on the faculty at the school of public health) found that stem cell researchers often ply journalists with "unrealistic timelines" for the development of stem cell therapies, and journalists often swallow these claims uncritically.
The authors mostly blame the scientists, who need to be more aware of "the importance of conveying realistic ... timelines to the popular press." We wouldn't give journalists this much of a pass; writers on scientific topics should understand that the development of drugs and therapies can take years and involve myriad dry holes and dead ends. They should be vigilant against gaudy promises.
That's especially true in stem...
Related Articles
By Virginia Heffernan, The New Republic | 05.29.2026
Here and there, it’s been a good month for humanity—or “magnificas humanitas,” as Pope Leo XIV calls us poor featherless bipeds.
On May 25, the pope published his encyclical letter “on safeguarding the human person in the time of artificial...
By Sonya Borrero, Christine Dehlendorf, and Rachel Logan, Stat | 05.01.2026
America is worried about fertility rates — again.
Coverage of the country’s declining birth rate reflects widespread unease: Families are struggling, young adults are delaying or forgoing parenthood, and the future labor force feels uncertain. These concerns are rooted in...
By Emile P. Torres, Truthdig | 04.27.2026
The CEO of OpenAI, Sam Altman, is on a messianic mission to bring about the singularity, the moment at which artificial intelligence begins to self-improve. If AI is smart enough to build the next generation of even smarter AI...
By Marcelo Jauregui-Volpe, Wired | 04.24.2026
Two companies that launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict.
One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers...